Motor Neurone Disease Clinical Trial Update
Released
Released
Announcement PDF
Motor Neurone Disease Phase 1/2 Clinical Trial Update
• MPL well tolerated by all MND patients at the first two dosing levels
• No reported safety issues or Serious Adverse Events (SAEs)
• Pharmacokinetic (PK) analysis underway
22 May 2023 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage
biotechnology company evaluating the use of Monepantel (MPL) in Motor Neurone Disease (MND), is
pleased to provide an update on the Motor Neurone Phase 1/2 Clinical Trial.
The trial patients living with MND/Amyotrophic Lateral Sclerosis (MND/ALS) were evaluated for adverse
events. The Trial Safety Committee confirmed there were no reported safety issues or SAEs.
Subject to PK data confirming absorption as it did for Cohort 1, all six patients from Cohort 1 will be
elevated to Cohort 3 and will receive an increased dosage. The trial is open label and comprises a fourweek escalating dose of MPL. The Phase 1/2 MND trial is on track to be completed in Q3 of 2023.
Progress update on Phase 1/2 MND interim analysis
As announced on 2 March 2023, the Principal Investigator recommended undertaking an interim
analysis of preliminary biomarkers and efficacy markers on completion of dosing of the last patient of
Cohort 2.
PharmAust confirms that all blood samples from the interim analysis have been collected from all 12
patients in Cohorts 1 and 2 and have been submitted for analysis. Results will be announced to the
market as they are received. The pharmacokinetics study results, which were received last week on
time, will be formally interpreted by a pharmacologist and biostatistician and will be announced
imminently. An analysis evaluating changes in biomarkers and pharmacodynamics is still pending.
MPL is a promising treatment for MND
According to the International Alliance of ALS/MND Associations, MND affects over 350,000 people
globally and kills more than 100,000 people yearly. The disease is invariably fatal, with the average life
expectancy of someone with MND being around 27 months. The MND/ALS addressable market is
US$3.6Bn per annum, with Riluzole already reaching ~US$1Bn annual sales.
The disease is progressive, meaning the symptoms get worse over time. MND has no cure and no
effective treatment to reverse its progression. PharmAust notes that five patients have surpassed the
6-month mark on MPL without any safety issues, and one patient appears “stable”.
PharmAust demonstrated in its preclinical programs that MPL has the potential to activate molecular
pathways relevant to the treatment of MND. MPL could reduce the rate of degeneration and loss of
motor neurons in the brainstem's anterior horns and motor nuclei. There are also several surrogate
clinical endpoints to be determined during the trial. PharmAust has developed and manufactured a
bespoke MPL tablet for the trial.
PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia
Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com
With success in the clinic, PharmAust hopes that MPL could receive orphan drug designation by the
TGA and FDA for motor neurone disease. Such designations come with financial and supportive
benefits and PAA is evaluating this opportunity.
The Phase 1/2 study is being funded by a commitment of $881,085 by FightMND, Australia's largest
independent funder of MND research.
The Board authorises this announcement.
Enquiries:
Anusha Aubert
Investor Relations
investorenquiries@pharmaust.com
P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com
About PharmAust Limited:
PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange
(code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company
specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported
by PAA’s subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated $3.4
million in sales of goods & services in FY 2022.
PAA’s lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a
pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in
Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans,
demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs.
PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as
neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.
PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia
Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com
Share your feedback
Discover